Pfizer Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
PFIZER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Smallcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pfizer Limited reported revenue from operations of ₹2,519.65 crore for FY2026, up 10.4% from ₹2,281.35 crore in the previous year. However, net profit declined 5.9% to ₹722.43 crore from ₹767.60 crore, impacted by exceptional items of ₹49.16 crore (personnel separation costs of ₹41.73 crore due to Cipla distribution agreement and ₹7.43 crore for new labour code provisions). EPS stood at ₹157.92 versus ₹167.79 in FY2025. The company declared an unmodified audit opinion and recommended a final dividend of ₹75 per share (750%). Operating cash flow remained strong at ₹967.57 crore.
Revenue growth was moderate at 10.4%, but profit declined due to one-time restructuring charges. The clean audit opinion and strong cash flow are positives for shareholders. The ₹75 dividend signals confidence despite lower profitability.